Siemens Fonds Invest GmbH Reduces Stock Position in Moderna, Inc. (NASDAQ:MRNA)

Siemens Fonds Invest GmbH lowered its position in shares of Moderna, Inc. (NASDAQ:MRNA) by 52.2% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 4,351 shares of the company’s stock after selling 4,749 shares during the quarter. Siemens Fonds Invest GmbH’s holdings in Moderna were worth $181,000 at the end of the most recent quarter.

Several other institutional investors have also added to or reduced their stakes in MRNA. Wilmington Savings Fund Society FSB raised its holdings in Moderna by 295.0% in the 4th quarter. Wilmington Savings Fund Society FSB now owns 786 shares of the company’s stock worth $33,000 after purchasing an additional 587 shares in the last quarter. Compass Planning Associates Inc bought a new position in Moderna in the 4th quarter worth $37,000. Venturi Wealth Management LLC raised its holdings in Moderna by 286.2% in the 4th quarter. Venturi Wealth Management LLC now owns 896 shares of the company’s stock worth $37,000 after purchasing an additional 664 shares in the last quarter. Crowley Wealth Management Inc. bought a new position in Moderna in the 4th quarter worth $41,000. Finally, Itau Unibanco Holding S.A. raised its holdings in Moderna by 51.2% in the 4th quarter. Itau Unibanco Holding S.A. now owns 1,013 shares of the company’s stock worth $42,000 after purchasing an additional 343 shares in the last quarter. Hedge funds and other institutional investors own 75.33% of the company’s stock.

Moderna Stock Performance

NASDAQ:MRNA opened at $24.86 on Monday. The firm has a market cap of $9.61 billion, a P/E ratio of -2.68 and a beta of 1.99. Moderna, Inc. has a fifty-two week low of $23.15 and a fifty-two week high of $170.47. The firm has a 50-day simple moving average of $27.87 and a two-hundred day simple moving average of $35.44.

Moderna (NASDAQ:MRNA) last released its quarterly earnings data on Thursday, May 1st. The company reported ($2.52) earnings per share for the quarter, beating analysts’ consensus estimates of ($2.92) by $0.40. The business had revenue of $108.00 million during the quarter, compared to analyst estimates of $130.35 million. Moderna had a negative net margin of 110.04% and a negative return on equity of 28.74%. Moderna’s revenue was down 35.3% compared to the same quarter last year. During the same period last year, the business earned ($3.07) EPS. On average, equities research analysts predict that Moderna, Inc. will post -9.61 EPS for the current year.

Analysts Set New Price Targets

Several research analysts have commented on MRNA shares. Barclays decreased their price objective on shares of Moderna from $45.00 to $40.00 and set an “equal weight” rating for the company in a report on Friday, May 2nd. The Goldman Sachs Group lowered shares of Moderna from a “buy” rating to a “neutral” rating and decreased their price objective for the stock from $99.00 to $51.00 in a report on Wednesday, January 29th. JPMorgan Chase & Co. decreased their price objective on shares of Moderna from $40.00 to $33.00 and set an “underweight” rating for the company in a report on Friday, March 21st. Evercore ISI decreased their price objective on shares of Moderna from $50.00 to $32.00 and set an “in-line” rating for the company in a report on Friday, May 2nd. Finally, Royal Bank of Canada lowered their price target on shares of Moderna from $32.00 to $28.00 and set a “sector perform” rating for the company in a research report on Friday, May 2nd. Four equities research analysts have rated the stock with a sell rating, fifteen have given a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $53.95.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.